KG PharmaConsulting Ltd - Accounts to registrar (filleted)

REGISTERED NUMBER: 09125819 (England and Wales)

KG PHARMACONSULTING LTD

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 28 FEBRUARY 2026

Page

Company Information

1

Statement of Financial Position

2

Notes to the Financial Statements

4

DIRECTORS:

K A Gunawardena

B A Gunawardena

SECRETARY:

B A Gunawardena

REGISTERED OFFICE:

Cherry Trees

Allendale Avenue

Worthing

West Sussex

BN14 0AH

REGISTERED NUMBER:

09125819 (England and Wales)

ACCOUNTANTS:

Morris Crocker

Chartered Accountants

Lake House

2 Port Way

Port Solent

Portsmouth

Hampshire

PO6 4TY

FIXED ASSETS

Property, plant and equipment

4

41,225

50,800

CURRENT ASSETS

Debtors

5

5,955

32,031

Cash at bank

30,482

11,571

36,437

43,602

CREDITORS

Amounts falling due within one year

6

9,889

9,787

NET CURRENT ASSETS

26,548

33,815

TOTAL ASSETS LESS CURRENT
LIABILITIES

67,773

84,615

CREDITORS

Amounts falling due after more than one
year

7

67,213

69,044

NET ASSETS

560

15,571

CAPITAL AND RESERVES

Called up share capital

8

10

Retained earnings

9

550

15,561

SHAREHOLDERS' FUNDS

560

15,571

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 28 February 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 28 February 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 17 April 2026 and were signed on its behalf by:

K A Gunawardena - Director

1.	STATUTORY INFORMATION

KG PharmaConsulting Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover represents net invoiced sales of goods and services, excluding value added tax.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings

-

20% on reducing balance

Motor vehicles

-

25% on reducing balance

Computer equipment

-

50% on cost

Financial instruments

The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, loans from banks and other third parties and loans to related parties and investments in non-puttable ordinary shares.

Trade and other debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and on hand, deposits with banks and other short-term highly liquid investments and bank overdrafts. In the balance sheet, bank overdrafts are shown within borrowings or current liabilities.

Trade and other creditors

Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2025 - 2 ) .

4.	PROPERTY, PLANT AND EQUIPMENT

Fixtures

and

Motor

Computer

fittings

vehicles

equipment

Totals

£

COST

At 1 March 2025

125

89,083

14,827

104,035

Additions

-

2,564

At 28 February 2026

125

89,083

17,391

106,599

DEPRECIATION

At 1 March 2025

74

38,974

14,187

53,235

Charge for year

10

10,527

1,602

12,139

At 28 February 2026

84

49,501

15,789

65,374

NET BOOK VALUE

At 28 February 2026

41

39,582

1,602

41,225

At 28 February 2025

51

50,109

640

50,800

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2026

2025

£

Trade debtors

2,400

-

Directors' current accounts

3,555

26,459

Corporation tax recoverable

-

5,515

VAT

-

57

5,955

32,031

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2026

2025

£

Hire purchase contracts

7,535

8,013

VAT

741

-

Other creditors

13

175

Accrued expenses

1,600

1,599

9,889

9,787

7.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR

2026

2025

£

Hire purchase contracts

67,213

69,044

8.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

2026

2025

value:

£

10

Ordinary

£1

10

9.

RESERVES

Retained

earnings

£

At 1 March 2025

15,561

Deficit for the year

(13,011

)

Dividends

(2,000

)

At 28 February 2026

550

10.	DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 28 February 2026 and 28 February 2025:

2026

2025

£

K A Gunawardena

Balance outstanding at start of year

13,229

8,820

Amounts advanced

1,777

13,229

Amounts repaid

(13,229

)

(8,820

)

Amounts written off

-

Amounts waived

-

Balance outstanding at end of year

1,777

13,229

B A Gunawardena

Balance outstanding at start of year

13,229

8,805

Amounts advanced

1,777

13,229

Amounts repaid

(13,229

)

(8,805

)

Amounts written off

-

Amounts waived

-

Balance outstanding at end of year

1,777

13,229

11.	ULTIMATE CONTROLLING PARTY

The company is under the control of Mr K Gunawardena and Mrs B Gunawardena and each own 50% of the issued share capital